Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 298, Issue 6, 2010, Pages

  Finch, Jane L ^a   Tokumoto, Masanori ^a,c   Nakamura, Hironori ^a,d   Yao, Wei ^b   Shahnazari, Mohammad ^b   Lane, Nancy ^b   Slatopolsky, Eduardo ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Kyushu Dental College   (Japan)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone formation and bone resorption; Calcimimetics; Hyperphosphatemia; Uremia; Vitamin D

Indexed keywords

CALCITRIOL; CINACALCET; CREATININE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG EFFECT; DRUG INFORMATION; FEMALE; HORMONE INHIBITION; HYPERPHOSPHATEMIA; HYPOCALCEMIA; MORPHOMETRICS; NEPHRECTOMY; NONHUMAN; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RAT; UREMIA;

EID: 77952718903     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00552.2009     Document Type: Article

References (44)

1. Bacic D, Wagner CA, Hernando N, Kaissling B, Biber J, Murer H. Novel aspects in regulated expression of the renal type IIa Na/Pi cotransporter. Kidney Int Suppl 91: S5-S12, 2004.
2. Bikle DD. Clinical counterpoint: Vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev 13: 765-784, 1992.
3. Block GA, Martin KJ, de Francisco A, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2003.
4. Brown AJ, Ritter CS, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses PTH synthesis and secretion. J Clin Invest 84: 728-732, 1989.
5. 3 receptors are decreased in parathyroid glands from chronically uremic dogs. Kidney Int 35: 19-23, 1989.
6. Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, Klassen PS, McCary LC, Pichette V. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46: 58-67, 2005.
7. Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCL in participants with CKD not receiving dialysis. Am J Kidney Dis 53: 197-207, 2009.
8. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47: 263-276, 2006. (Pubitemid 43121329)
9. Datta HK, MacIntyre I, Zaidi M. The effect of extracellular calcium elevation on morphology and function of isolated rat osteoclasts. Biosci Rep 9: 747-751, 1989.
10. Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 36: 1093-1098, 1989.
11. Dusso AS, Negrea L, Finch J, Kamimura S, Lopez-Hilker S, Mori T, Nishii Y, Brown A, Slatopolsky E. The effect of 22-oxacalcitriol on serum calcitriol. Endocrinology 130: 3129-3134, 1992.
12. 2+-sensing receptor promotes loss of cancellous bone. Endocrinology 148: 3156-3163, 2009.
13. 2 on inducing differentiation and markers of bone formation in MG-63 cells. J Am Soc Nephrol 12: 1468-1474, 2001.
14. Fox J, Lowe SH, Conklin RL, Nemeth EF. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine 10: 97-103, 1999.
15. Franceschi RT, James WM, Zerlauth G. 1 alpha, 25-dihydroxy-vitamin D3 specific regulation of growth, morphology and fibronectin in a human osteosarcoma cell line. J Cell Physiol 123: 401-409, 1985.
16. Gogusev JT, Duchambon P, Hory BM, Giovannini M, Goureau Y, Sarfati E, Drüeke TB. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51: 328-336, 1997. (Pubitemid 27064555)
17. Henry HL, Norman AW. Vitamin D: metabolism and biological actions. Annu Rev Nutr 4: 493-520, 1984.
18. Kameda T, Mano H, Yamada Y, Takai H, Amizuka N, Kobori M, Izumi N, Kawashima H, Ozawa H, Ikeda K, Kameda A, Hakeda Y, Kumegawa M. Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells. Biochem Biophys Res Commun 245: 419-422, 1998. (Pubitemid 28418516)
19. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005.
20. Kifor O, Moore FD, Wang P, Goldstein M, Vassilev P, Kifor I, Hebert SC, Brown EM. Reduced immunostaining for the extracellular Ca sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81: 1598-1606, 1996. (Pubitemid 126423257)
21. Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR, Ghishan FK. 1,25-dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link to a renalgastrointestinal- skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-G1042, 2005.
22. 3H] 1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316: 1577-1582, 1997.
23. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus product in secondary hyperparathyroidism. Kidney Int 63: 248-254, 2003. (Pubitemid 35463928)
24. Malluche HH, Monier-Faugere MC, Wang G, Frazã OJM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69: 269-278, 2009. (Pubitemid 351516270)
25. Mentaverri R, Yano S, Chattopadhyay N, Petit L, Kifor O, Kamel S, Terwilliger EF, Brazier M, Brown EM. The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB J 20: 2562-2564, 2006. (Pubitemid 44953781)
26. 3 receptor in experimental uremia. Kidney Int 32: 350-353, 1987.
27. Nemeth EF, Steffey ME, Hammerland LG. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95: 4040-4045, 1998.
28. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 52: 3-9, 1997.
29. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14: 575-583, 2003.
30. 2D of transcription of the parathyroid hormone gene. Endocrinology 119: 2864-2866, 1985.
31. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N. Circulating FGF-23 is regulated by 1α,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280: 2543-2549, 2005.
32. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004.
33. Shimada T, Katitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of FGF-23 demonstrates essential physiological role for FGF-23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004.
34. Silver J, Russell J, Sherwood LM. Regulation by vitamin D metabolites of messenger RNA for pre-pro-parathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82: 4270-4273, 1985.
35. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78: 1296-1301, 1986.
36. Silver J, Bar Sela S, Naveh-Many T. Regulation of parathyroid cell proliferation. Curr Op Nephrol Hyperten 6: 321-326, 1997.
37. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Jüppner H, Lanske B. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypohphosphatemia in Phex-deficient mice. Matrix Biol 23: 421-432, 2004. (Pubitemid 39576657)
38. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin K. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74: 2136-2143, 1984. (Pubitemid 15197358)
39. 2, suppresses parathyroid hormone secretion in the absence of hypercalcemia. Am J Kidney Dis 26: 852-860, 1995.
40. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97: 2534-2540, 1996. (Pubitemid 26187341)
41. Slatopolsky E, Brown AJ, Dusso AS. Pathogenesis of secondary hyperparathyroidism. Kidney Int 56, Suppl 73: S14-S19, 1999.
42. 2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney Int 63: 2020-2027, 2003.
43. Yajima A, Akizawa T, Tsukamoto Y, Kurihara S, Ito A. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism. Ther Apher Dial 1: S38-S43, 2008. (Pubitemid 351490244)
44. Yamaguchi T, Chattopadhyay N, Kifor O, Butters RR Jr, Sugimoto T, Brown EM. Mouse osteoblastic cell line (MC3Tc-E1) expresses extracellular calcium (Ca2=o)-sensing receptor and its agonists stimulate chemotaxis and proliferation of MC3T3-E1 cells. J Bone Miner Res 13: 1530-1538, 1998. (Pubitemid 28465293)